Minaxi Jhawer

Summary

Affiliation: Montefiore Medical Center
Country: USA

Publications

  1. ncbi Phase II trial of nolatrexed dihydrochloride [Thymitaq, AG 337] in patients with advanced hepatocellular carcinoma
    Minaxi Jhawer
    Montefiore Medical Center, NY, USA
    Invest New Drugs 25:85-94. 2007
  2. ncbi Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma
    Manish A Shah
    Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, and the Weill School of Medicine, Cornell University, New York, NY, USA
    J Clin Oncol 29:868-74. 2011
  3. ncbi PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab
    Minaxi Jhawer
    Department of Oncology, Montefiore Medical Center, Albert Einstein Cancer Center, Bronx, NY 10467, USA
    Cancer Res 68:1953-61. 2008
  4. ncbi Phase I clinical trial of irinotecan with oral capecitabine in patients with gastrointestinal and other solid malignancies
    Sanjay Goel
    Department of Hematology/Oncology, Montefiore Medical Center/Albert Einstein College of Medicine and Albert Einstein Comprehensive Cancer Center Bronx, NY 10461, USA
    Am J Clin Oncol 25:528-34. 2002

Detail Information

Publications4

  1. ncbi Phase II trial of nolatrexed dihydrochloride [Thymitaq, AG 337] in patients with advanced hepatocellular carcinoma
    Minaxi Jhawer
    Montefiore Medical Center, NY, USA
    Invest New Drugs 25:85-94. 2007
    ..To evaluate the tolerability and efficacy of nolatrexed in patients with advanced hepatocellular carcinoma...
  2. ncbi Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma
    Manish A Shah
    Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, and the Weill School of Medicine, Cornell University, New York, NY, USA
    J Clin Oncol 29:868-74. 2011
    ..To evaluate the safety and efficacy of a modified administration schedule of docetaxel, cisplatin, and fluorouracil (mDCF) with bevacizumab in patients with advanced gastroesophageal malignancies...
  3. ncbi PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab
    Minaxi Jhawer
    Department of Oncology, Montefiore Medical Center, Albert Einstein Cancer Center, Bronx, NY 10467, USA
    Cancer Res 68:1953-61. 2008
    ..A priori screening of colon tumors for PTEN expression status and PIK3CA and Ras/BRAF mutation status could help stratify patients likely to benefit from this therapy...
  4. ncbi Phase I clinical trial of irinotecan with oral capecitabine in patients with gastrointestinal and other solid malignancies
    Sanjay Goel
    Department of Hematology/Oncology, Montefiore Medical Center/Albert Einstein College of Medicine and Albert Einstein Comprehensive Cancer Center Bronx, NY 10461, USA
    Am J Clin Oncol 25:528-34. 2002
    ..The combination of irinotecan 275 mg/m(2) and capecitabine 2,300 mg/d represents a safe, favorable, and convenient outpatient regimen warranting further phase II evaluation...